Skip to main content
Adicet Bio, Inc. logo

Adicet Bio, Inc. — Investor Relations & Filings

Ticker · ACET ISIN · US0070021086 US Manufacturing
Open in API
Filings indexed 633 across all filing types
Latest filing 2026-05-20 Annual Report
Country US United States of America
Listing US ACET

About Adicet Bio, Inc.

https://www.adicetbio.com/

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies. The company's core mission is to create 'off-the-shelf' treatments for patients with cancer and autoimmune diseases. By engineering gamma delta T cells, Adicet aims to provide readily available and potent immunotherapies. Its proprietary platform is designed to leverage the unique characteristics of these cells, which possess both innate and adaptive immune properties, to develop potentially first-in-class and best-in-class therapeutic candidates that can effectively target and eliminate diseased cells.

Recent filings

Filing Released Lang Actions
10-K/A
Annual Report FY 2025
2026-05-20 English
10-Q - Adicet Bio, Inc. (0001720580) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Adicet Bio, Inc. (0001720580) (Filer)
Regulatory Filings Classification · 93% confidence The document is a Current Report on Form 8-K filed with the SEC. It furnishes a press release (Exhibit 99.1) announcing quarterly results but does not itself include substantive financial tables or detailed earnings content. It is a regulatory compliance filing under the Securities Exchange Act and does not match specific categories like ER (since the actual release text is not included), IR (no full interim report), RPA, etc. This falls under the general “Regulatory Filings” category.
2026-05-13 English
8-K - Adicet Bio, Inc. (0001720580) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an unregistered sale of equity securities involving a pre-funded warrant exchange, which is a capital raising or financing activity. The document does not contain full financial statements or detailed financial performance data, but rather an announcement of a financing transaction. Therefore, it fits best under the category for Capital/Financing Update (CAP). The document length is about 5007 characters, which is consistent with a detailed announcement rather than a brief notice or a full report like an Annual or Interim Report.
2026-04-28 English
EFFECT - Adicet Bio, Inc. (0001720580) (Filer)
Regulatory Filings
2026-03-24 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.